June 8, 2023 – DelNova to be featured in the upcoming list of Top 10 Biotech Startups 2022 as Editor’s Choice, on Life Sciences Review Magazine…...
April 1, 2023 DelNova patent allowed in Europe: EP 3454855 A1 20190320 (EN) “TREATING OF SIDE-EFFECTS RESULTING FROM CHEMODENERVATION”...
DelNova to be featured in the upcoming list of Top 10 Biotech Startups 2022 as Editor’s Choice, on Life Sciences Review Magazine...
Watch the video presentation....
Presentation to highlight ReViVox™, DelNova's lead product candidate designed for treating complications resulting from undesirable muscle paralysis following botulinum neurotoxin (e.g. Botox®) procedures SAN DIEGO and CHICAGO, May 29, 2019 /PRNewswire/ -- DelNova, a biopharmaceutical company developing clinically validated molecules linked to advances in drug delivery, announced today that its...
